CNBX Pharmaceuticals Management
Management criteria checks 3/4
CNBX Pharmaceuticals' CEO is Eyal Barad, appointed in Jan 2018, has a tenure of 4.42 years. total yearly compensation is $268.72K, comprised of 94% salary and 6% bonuses, including company stock and options. directly owns 0.093% of the company’s shares, worth €4.16K. The average tenure of the management team and the board of directors is 4.4 years and 3.6 years respectively.
Key information
Eyal Barad
Chief executive officer
US$268.7k
Total compensation
| CEO salary percentage | 94.0% |
| CEO tenure | 4.4yrs |
| CEO ownership | 0.09% |
| Management average tenure | 4.4yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Feb 28 2022 | n/a | n/a | -US$5m |
| Nov 30 2021 | n/a | n/a | -US$4m |
| Aug 31 2021 | US$269k | US$253k | -US$3m |
| May 31 2021 | n/a | n/a | -US$3m |
| Feb 28 2021 | n/a | n/a | -US$3m |
| Nov 30 2020 | n/a | n/a | -US$3m |
| Aug 31 2020 | US$241k | US$222k | -US$7m |
| May 31 2020 | n/a | n/a | -US$8m |
| Feb 29 2020 | n/a | n/a | -US$8m |
| Nov 30 2019 | n/a | n/a | -US$3m |
| Aug 31 2019 | US$276k | US$258k | US$1m |
| May 31 2019 | n/a | n/a | US$2m |
| Feb 28 2019 | n/a | n/a | US$1m |
| Nov 30 2018 | n/a | n/a | -US$4m |
| Aug 31 2018 | US$207k | US$207k | -US$4m |
Compensation vs Market: Eyal's total compensation ($USD268.72K) is below average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: Eyal's compensation has increased whilst the company is unprofitable.
CEO
Eyal Barad (56 yo)
4.4yrs
Tenure
US$268,716
Compensation
Mr. Eyal Barad is the Co- Founder of Cannabics Pharmaceuticals Inc. and has been its Chief Executive Officer since January 29, 2018 and Director since November 1, 2017 and served as its Chief Operating Off...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$241.79k | 0% € 0 | |
| Co-Founder | 4.4yrs | US$268.72k | 0.093% € 4.2k | |
| Co-Founder & CTO | 8.2yrs | US$225.63k | no data | |
| Chief Financial Officer | 5.6yrs | US$76.40k | no data | |
| Vice President of Public Relations & Investor Relations | no data | no data | no data | |
| Senior Advisor of Regulation | 5.3yrs | no data | no data | |
| Financial Advisor & Member of Advisory Board | no data | no data | no data | |
| Chief Data Officer | 4.3yrs | no data | no data | |
| Head of Cannabidiol Research | 2.5yrs | no data | no data | |
| Head of Neuropsychiatry Development | less than a year | no data | no data | |
| Member of Scientific Advisory Board and VP of R&D | no data | no data | no data | |
| Member of Scientific Advisory Board & VP of IP | no data | no data | no data |
4.4yrs
Average Tenure
56yo
Average Age
Experienced Management: 8C8's management team is considered experienced (4.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$241.79k | 0% € 0 | |
| Co-Founder | 4.6yrs | US$268.72k | 0.093% € 4.2k | |
| Senior Advisor of Regulation | 5.3yrs | no data | no data | |
| Financial Advisor & Member of Advisory Board | 5.3yrs | no data | no data | |
| Member of Scientific Advisory Board and VP of R&D | no data | no data | no data | |
| Member of Scientific Advisory Board & VP of IP | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Advisory Board | 2.2yrs | no data | no data | |
| Head of Advisory Board & Independent Director | 5.3yrs | US$60.00k | no data | |
| Member of Advisory Board | 5.3yrs | no data | no data | |
| Member of Advisory Board | 2yrs | no data | no data | |
| Member of Advisory Board | 1.8yrs | no data | no data |
3.6yrs
Average Tenure
57yo
Average Age
Experienced Board: 8C8's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/28 13:53 |
| End of Day Share Price | 2022/03/31 00:00 |
| Earnings | 2022/02/28 |
| Annual Earnings | 2021/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CNBX Pharmaceuticals Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|